Hartington Pharma Limited 06134802 false 2023-04-01 2024-03-31 2024-03-31 The principal activity of the company is the distribution of pharmaceutical preparations. Digita Accounts Production Advanced 6.30.9574.0 true true 06134802 2023-04-01 2024-03-31 06134802 2024-03-31 06134802 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-03-31 06134802 core:CurrentFinancialInstruments 2024-03-31 06134802 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 06134802 core:Non-currentFinancialInstruments 2024-03-31 06134802 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 06134802 bus:SmallEntities 2023-04-01 2024-03-31 06134802 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 06134802 bus:FilletedAccounts 2023-04-01 2024-03-31 06134802 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 06134802 bus:RegisteredOffice 2023-04-01 2024-03-31 06134802 bus:Director1 2023-04-01 2024-03-31 06134802 bus:Director2 2023-04-01 2024-03-31 06134802 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2023-04-01 2024-03-31 06134802 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 06134802 core:OtherRelatedParties 2023-04-01 2024-03-31 06134802 countries:EnglandWales 2023-04-01 2024-03-31 06134802 2022-04-01 2023-03-31 06134802 2023-03-31 06134802 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2023-03-31 06134802 core:CurrentFinancialInstruments 2023-03-31 06134802 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 06134802 core:Non-currentFinancialInstruments 2023-03-31 06134802 core:Non-currentFinancialInstruments core:AfterOneYear 2023-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 06134802

Hartington Pharma Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2024

 

Hartington Pharma Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 5

 

Hartington Pharma Limited

Company Information

Directors

Mr A L Levdanski Liashevski

Archil MTCHEDLIDZE

Registered office

124 City Road
London
EC1V 2NX

Accountants

Clever Accounts Limited
Brookfield Court
Selby Road
Leeds
LS25 1NB

 

Hartington Pharma Limited

(Registration number: 06134802)
Balance Sheet as at 31 March 2024

Note

2024
£

2023
£

Current assets

 

Debtors

60

642

Cash at bank and in hand

 

8

6,387

 

68

7,029

Creditors: Amounts falling due within one year

(411)

(75)

Total assets less current liabilities

 

(343)

6,954

Creditors: Amounts falling due after more than one year

(382,464)

(381,765)

Net liabilities

 

(382,807)

(374,811)

Capital and reserves

 

Called up share capital

4

1,000

1,000

Retained earnings

(383,807)

(375,811)

Shareholders' deficit

 

(382,807)

(374,811)

For the financial year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 25 March 2025 and signed on its behalf by:
 

.........................................

Mr A L Levdanski Liashevski
Director

 

Hartington Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
124 City Road
London
EC1V 2NX
England

These financial statements were authorised for issue by the Board on 25 March 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements are prepared on a going concern hasis. The company remains assured of the financial support by the immediate parent company, Hartington Business SL. The directors have received confirmation that the parent company will continue to support the company and provide it with adequate funds when necessary to enable it to meet its debts as they fall due in the foreseeable future. On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Hartington Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

 

Hartington Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2024

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

4

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

ordinary shares of £1 each

1,000

1,000

1,000

1,000

       

5

Loans and borrowings

Non-current loans and borrowings

2024
£

2023
£

Other borrowings

382,464

381,765

6

Related party transactions

Summary of transactions with other related parties

At the year end, a balance of £381,765 (2021: C340,996) is owed by Hartington Business SL, the immediate parenI undertaking. This amount is included in amounts owed by group undertakings. Amounts owed to group undertakings are unsecured, interest bearing at 2.5% per annum and repayable on demand.